Get the Weekly Intelligence Brief — top committee picks every Sunday.

LLY vs PFE

Eli Lilly and Company vs Pfizer Inc. — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
56
Buy
VS
PFE
Pfizer Inc.
48
Watch
MetricLLYPFE
AI Score 56 48
Price $1,233.40 $28.57
P/E Ratio 41.81× 36.96×
ROE 77.8% 9.0%
Revenue Growth YoY
Gross Margin 84.0% 71.3%
Debt / Equity 1.62× 0.74×
Dividend Yield 0.5% 6.1%
RSI (14) 59.0 71.3
Beta 0.506 0.28
Expected Upside +0.1% +2.7%

AI Committee View

Current Innellis committee reasoning for LLY versus PFE.
LLY leads by 8 points.

LLY scores 56/100 (Buy) versus PFE at 48/100 (Watch).

LLY Committee View
67% agreement
6 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 92.6% shows genuine earnings power backing the valuation — Value
  • Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
  • EPS growing 94.6% YoY — Growth
Bear Case
  • P/E of 43.2 is expensive by classic value standards — Value
  • Price-to-book of 38.3x prices in significant intangible value — Value
  • Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value
PFE Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — bollinger bandwidth of 16.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Dividend yield of 5.4% pays you to wait — Value
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
Bear Case
  • P/E of 35.2 is moderate-to-rich — Value
  • ROE of only 4.9% -- cheap may mean cheap for a reason — Value
  • Revenue declining -0.2% YoY -- this is not a growth story right now — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
LLY Full Analysis PFE Full Analysis